<DOC>
	<DOCNO>NCT02906124</DOCNO>
	<brief_summary>To evaluate outcome pregnancy female diagnose familial hypercholesterolaemia ( FH ) , expose Repatha® pregnancy . This include follow-up infant age 12 month</brief_summary>
	<brief_title>Study Evaluate Safety Repatha® Pregnancy</brief_title>
	<detailed_description>Women diagnose familial hypercholesterolaemia ( FH ) , treat centre Europe , South Africa Australia , pregnancy confirm study observation period provide informed consent participate study . Exposed subject woman receive Repatha® pregnancy and/or breastfeeding ; unexposed subject woman receive Repatha® pregnancy and/or breast-feeding . In infant , exposure may occur utero and/or via breast milk , within 15 week follow date Repatha® dosing mother</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Females diagnose Familial hypercholesterolaemia ( FH ) . Confirmed pregnancy study observation period . Provided informed consent followup study , subject infant ( ) bear study observation period There exclusion criterion</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>hypercholesterolaemia</keyword>
	<keyword>Lipid lower therapy</keyword>
	<keyword>Pregnancy</keyword>
</DOC>